LoadingLoadingLoadingThe quick read
Latest quote·Oct 14
Net selling: insiders sold $6.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $6.5M and bought $0 of REGN stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. $6.5M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Murphy, Andrew J (Co-Chief Scientific Officer), who sold $3.2M. The latest filing was on Oct 15, 2026.
None. No member of Congress disclosed a REGN trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
Millennium
$142.9M
added
Susquehanna
$88.7M
added
Qube Research
$73.8M
added
Buys (1)
No tracked top-trader positions in REGN right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Financial period
Q2 2026
Adjusted EPS
$10.21 expected
Revenue
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $14.29 / $10.21Yahoo Finance | +39.99% beat | $4.29B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 29, 2026 | $9.47 / $8.90Yahoo Finance | +6.38% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Jan 30, 2026 | $11.44 / $10.75Yahoo Finance | +6.38% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $11.83 / $9.64Yahoo Finance | +22.66% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 1, 2025 | $12.89 / $8.44Alpha Vantage | +52.73% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | $8.22 / $8.48Alpha Vantage | -3.07% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 4, 2025 | $12.07 / $11.19Alpha Vantage | +7.86% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $12.46 / $11.70Alpha Vantage | +6.50% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 15, 2026
EPS expected
$14.53 to $17.68
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Cost of what it sold | $521.6M | $584.6M | $669.4M | $576.5M |
| Gross profit | $3.23B | $3.30B | $2.94B | $3.71B |
| What it spent | ||||
| Research and development | $1.56B | $1.63B | $1.65B | $1.63B |
| Sales and admin | $657.8M | $775.0M | $647.7M | $662.1M |
| Total operating expenses | $2.21B | $2.42B | $2.29B | $2.29B |
| What was left | ||||
| Operating profit | $1.03B | $879.9M | $642.9M | $1.42B |
| Interest on debt | $19.3M | $12.2M | $12.9M | $11.0M |
| Profit before tax | $1.76B | $1.04B | $831.2M | $1.53B |
| Tax | $303.3M | $199.1M | $104.0M | $230.9M |
| Net profit | $1.46B | $844.6M | $727.2M | $1.30B |
| EBITDA | $1.92B | $1.20B | $967.3M | $1.66B |
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
RBC raises target for Regeneron stock to USD 810.00
NeutralOct 13Cantor Fitzgerald reiterates Overweight on CytomX stock, $12 target By Investing.com
NeutralOct 13Regeneron reports Pasatru data and Citi holds Regeneron stock
Leans bullishOct 13Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95
BullishOct 13Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month
BullishOct 12Regeneron’s New Drug Halts Rogue Bone Growth Effectively - Regeneron Pharmaceuticals (NASDAQ:REGN)
BullishOct 12Regeneron Says Pasatru Showed Sustained Benefit in OPTIMA Trial Extension for Genetic Disorder
BullishOct 12Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
BullishOct 12